Medytox Inc.
Overview
History
R&D
Global Network
History

Take-off / 2009~Present

2012Held Osong cGMP Plant Groundbreaking Ceremony
Received Innovative Pharmaceutical Company Accreditation
Approval from KFDA for Upper-limb Post-stroke Spasticity
2011 Selected as a World-class Advanced Technology Center in 2011 by Ministry
  of Knowledge Economy
KGMP approval for Neuramis® in Ochang Plant
Approval for Global Clinical trial phase 2 of the next generation botulinum
  toxin in Australia

Received $10M Export Tower Award
Approval from KFDA for Clinical Trial of Neuramis®
Received CE mark for Neuramis®
2010Marketing approval from KFDA for Meditoxin® 50U
Therapeutic indication approval from KFDA for cerebral palsy
Approval for Global trial phase I of the next generation botulinum toxin in Australia
2009Listed on KOSDAQ
Marketing approval from KFDA for Meditoxin® 200U
Received $5M Export Tower Award
Achived No.1 Market Share in the Botulinum Toxin Marketing korea

Growth / 2006~2008

2008Selected as a Promising Export Company
by the Small and Medium-sized Business Administration
2007Opend Medytox Seoul office 2006Marketing approval from KFDA for Meditoxin
Selected as a World-class Product by the Ministry of Industry and Resources

Beginning / 2000~2005

2004KGMP approval for Chungbuk Ochang Plant Selected for the
Botulinum-toxin-originating Active-candidate
2002Complited Chungbuk Ochang KGMP Plant construction 2001Established the Microbial Toxin R&D Center 2000Established Medytox Inc.

Medytox Mini Poll

Which area do your patients most want to be treated with Neuronox?
a. Glabellar lines
b. Crow’s feet
c. Forehead lines
d. Masseter
e. Calf
MoreMedytox News